Kiniksa Pharmaceuticals, Ltd. KNSA 深 沪
已收盘 08-21 16:00:00 美东时间
79.03
+0.560
+0.71%
华盛通- 最 高79.93
- 今 开78.28
- 成交量 27.01万股
- 最 低 78.01
- 昨 收 78.47
- 总市值 61.66亿
- 52周最高 82.94
- 市盈率 静 105.78
- 换手率 0.35%
- 52周最低 33.45
- 委 比 96.40%
- 总股本 7802.40万
- 历史最高 82.94
- 量 比 0.54
- 振 幅 2.45%
- 历史最低 5.01
- 每 手 1
- 风险率 11.40%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Kiniksa Pharmaceuticals to Present at Canaccord Genuity 46th Annual Growth Conference
Kiniksa Pharmaceuticals International, plc announced that its management will participate in a fireside chat at the Canaccord Genuity 46th Annual Growth Conference on August 12, 2026, at 9:00 a.m. ET. A live webcast and replay of the presentation will be available on the company’s website. Kiniksa is a biopharmaceutical company focused on developing novel therapies for diseases with unmet needs, particularly in cardiovascular indications.
08-07 20:01
美股大行评级 | 绩后重锤！Meta惨遭16家大行下调目标价；高通、Arm、泛林集团、波士顿科学也遭多家大行下调目标价
今日重点评级关注：HC Wainwright & Co.：维持TOMI Environmental Solutions"买入"评级，目标价从3.5美元升至7美元；Canaccord Genuity：维持Viking Therapeutics"买入"评级，目标价从107美元升至114美元
07-31 11:43
Goldman Sachs Maintains Buy on Kiniksa Pharmaceuticals, Raises Price Target to $90
Goldman Sachs analyst Paul Choi maintains Kiniksa Pharmaceuticals (NASDAQ:KNSA) with a Buy and raises the price target from $75 to $90.
07-31 02:42
美股牛股 | AI基建股IOND首日升近26%，为21年来最大直接上市项目；Lucid劲升21%
AI基建股IOND首日升近26%，为21年来最大直接上市项目；医药股PMN飙升23%，阿尔茨海默病药物试验结果积极；Lucid劲升21%，获沙特首富1.3亿美元投资>>
07-29 19:00
Kiniksa tops Q2 estimates on Regeneron-partnered Arcalyst
Kiniksa Pharmaceuticals (KNSA) added nearly 50% on Tuesday after posting another quarterly beat and guidance boost with its financials, thanks mainly to Arcalyst, a heart disease therapy it markets wi...
07-29 02:29
Kiniksa Pharmaceuticals Q2 EPS $0.30 Beats $0.27 Estimate, Sales $243.600M Beat $225.457M Estimate
Kiniksa Pharmaceuticals (NASDAQ:KNSA) reported quarterly earnings of $0.30 per share which beat the analyst consensus estimate of $0.27 by 11.11 percent. This is a 30.43 percent increase over earnings of $0.23 per share from the same period last year. The company reported quarterly sales of $243.600...
07-28 19:31
Kiniksa Pharmaceuticals Raises FY2026 Sales Guidance from $930.000M-$945.000M to $980.000M-$995.000M vs $940.106M Est
Kiniksa Pharmaceuticals (NASDAQ:KNSA) raises FY2026 sales outlook from $930.000 million-$945.000 million to $980.000 million-$995.000 million vs $940.106 million estimate.
07-28 19:30
美股大行评级 | 谷歌绩后分歧大！4家大行上调、10家下调目标价；特斯拉遭8家大行下调目标价；ServiceNow、德州仪器、西屋制动、AT&T、CSX等获多家大行上调目标价
今日重点评级关注：伯恩斯坦：维持ServiceNow"跑赢大市"评级，目标价从236美元升至248美元；HC Wainwright & Co.：维持NovoCure"买入"评级，目标价从46美元升至52美元
07-24 11:37
Goldman Sachs Maintains Buy on Kiniksa Pharmaceuticals, Raises Price Target to $75
Goldman Sachs analyst Paul Choi maintains Kiniksa Pharmaceuticals (NASDAQ:KNSA) with a Buy and raises the price target from $60 to $75.
07-24 00:12
Kiniksa Pharmaceuticals to Report Second Quarter 2026 Financial Results on July 28, 2026
Kiniksa Pharmaceuticals International (Nasdaq: KNSA) announced it will host a conference call and live webcast on July 28, 2026, at 8:30 a.m. Eastern Time to discuss its Q2 2026 financial results and recent portfolio updates. The webcast will be available on its website, and participants can register via the provided link to join by phone. A replay will be accessible within 48 hours. Kiniksa focuses on developing novel therapies for unmet medical...
07-23 20:01
